ArticleInfectious diseases of poverty2022
A novel lytic phage potentially effective for phage therapy against Burkholderia pseudomallei in the tropics.
Article in Infectious diseases of poverty, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Eradication of catheter-associated MDR Acinetobacter baumannii biofilms mediated by novel phage encoded depolymerase activity.NPJ biofilms and microbiomes · 2026Article
- Isolation and characterization of Avs-1, a bacteriophage effective against the aquaculture pathogenApplied and environmental microbiology · 2026Article
- Drug screening to identify compounds to eliminateiScience · 2026Article
- Rapid Cavitary Pneumonia and Reversible Hepatic Injury in Burkholderia pseudomallei ST271 Infection.The American journal of case reports · 2026Article
- Genetic Engineering of Lysogenic-Lytic Switch Genes ImprovesInternational journal of molecular sciences · 2026Article
- Genomic diversity and clade clustering ofiScience · 2026Article
- Phage-mediated control of melioidosis in Southern China: molecular insights and therapeutic potential of N4-like viruses from Hainan.BMC microbiology · 2025Article
- Article
- Isolation and characterisation of Klebsiella pneumoniae bacteriophages vB_Kpn_Lilla1 and vB_Kpn_Lilla2.Archives of virology · 2025Article
- Characterization and genomic analysis of Sharanji: a jumbo bacteriophage of Escherichia coli.Virology journal · 2025Article
- SXP01: a novel bacteriophage for combatingFrontiers in microbiology · 2025Article
- Review
- Case Report: Burkholderia pseudomallei Infection with Sepsis and Aortic Pseudoaneurysm.The American journal of tropical medicine and hygiene · 2024Article
- Phage-induced efflux down-regulation boosts antibiotic efficacy.PLoS pathogens · 2024Article
- InducedFrontiers in microbiology · 2024Article
- Detection ofFrontiers in public health · 2023Article
- Effective Therapeutic Options for Melioidosis: Antibiotics versus Phage Therapy.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundBurkholderia pseudomallei is a tropical pathogen that causes melioidosis. Its intrinsic drug-resistance is a leading cause of treatment failure, and the few available antibiotics require prolonged use to be effective. This study aimed to assess the clinical potential of B. pseudomallei phages isolated from Hainan, China.
methodsBurkholderia pseudomallei strain (HNBP001) was used as the isolation host, and phages were recovered from domestic environmental sources, which were submitted to the host range determination, lytic property assays, and stability tests. The best candidate was examined via the transmission electron microscope for classification. With its genome sequenced and analyzed, its protective efficacy against B. pseudomallei infection in A549 cells and Caenorhabditis elegans was evaluated, in which cell viability and survival rates were compared using the one-way ANOVA method and the log-rank test.
resultsA phage able to lyse 24/25 clinical isolates was recovered. It was classified in the Podoviridae family and was found to be amenable to propagation. Under the optimal multiplicity of infection (MOI) of 0.1, an eclipse period of around 20 min and a high titer (10
conclusionsAs the first B. pseudomallei phage was isolated in Hainan, China, phage vB_BpP_HN01 was characterized by promising lytic property, stability, and efficiency of bacterial elimination during the in vitro/vivo experiments. Therefore, we can conclude that it is a potential alternative agent for combating melioidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.